Procter & Gamble Health Sep 2026 quarter: standalone PAT up 25.9 percent

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

PGHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹5699.50

prior close

₹5741.00

announcement price

In-mkt

timing

Nifty Microcap 250market+1.4%+0.4% vs market

Pharmaceuticals peers, median of 174sector+0.2%+1.7% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.2

10m

+1.4

15m

+2.1

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9+1.4+0.4+0.2+1.7

Next day

+3.1+1.7+1.4+0.6+2.5

+1.8+3.9-2.1+1.6+0.2

-1.9+5.1-7.0+2.3-4.2

-2.4pendingpending+2.3-4.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone quarter ended September 30, 2026: revenue Rs 38,249 lakh, up 17.7 percent from Rs 32,492 lakh a year earlier, and profit after tax Rs 11,151 lakh versus Rs 8,854 lakh. EBITDA margin rose to 39.8 percent from 37.0 percent. Standalone half year: revenue Rs 74,620 lakh, profit after tax Rs 20,766 lakh, including a Rs 3,180 lakh gain on the Worli office sale in the June quarter. Operating cash flow was Rs 19,086 lakh.

Likely market impact

Clean quarter profit growth of about 26 percent and a wider EBITDA margin should support the stock, though revenue growth stayed below 20 percent.

By the numbersStandalone · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹382.5 Cr	₹324.9 Cr	+17.7%
Operating profit	₹146.2 Cr	₹114.1 Cr	+28.1%
Profit after tax	₹111.5 Cr	₹88.54 Cr	+25.9%
EBITDA margin	39.8%	37.0%	+2.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.